Is Neuropace Inc (NPCE) overvalued? · rev $79.9M
Neuropace Inc (NPCE) is a medical devices company listed on US.
This page asks whether Neuropace Inc (NPCE) looks expensive on cached numbers — not a short thesis.
Latest reported NPCE revenue for 2024-12-31 was $79.9M. Net income was -$27.1M. Revenue was up 22.1% from 2023-12-31 to 2024-12-31. NPCE currently screens at market cap $312.2M.
NPCE currently screens at market cap $312.2M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next NPCE 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the NPCE stock page for the full model, not this heading.
Not investment advice.